Results for tag: "Brineura"

Brineura is a drug used to treat a rare, progressive neurological disorder known as late infantile neuronal ceroid lipofuscinosis type 2 (CLN2). It is a form of Batten disease, a group of inherited disorders that affect the nervous system. Brineura is the first and only approved treatment for CLN2, and is administered directly into the cerebrospinal fluid (CSF) of the brain. The drug works by slowing the progression of the disease, allowing patients to maintain their current level of functioning for a longer period of time. Brineura is part of the Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. These drugs are typically administered orally, intravenously, or directly into the CSF. The companies in the Brineura market include BioMarin Pharmaceuticals, which manufactures and markets the drug, as well as other pharmaceutical companies that develop and market CNS drugs. These include AbbVie, Biogen, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more